Mineralys Posts $57.3 Million Quarterly Loss
The Radnor, Pennsylvania drugmaker's loss widened as spending on its commercial preparations for its hypertension drug rose.
Updated on Nov. 11, 2026 in Healthcare

Mineralys Therapeutics reported a net loss of $57.3 million for the quarter ended Sept. 30, 2026, up from $36.9 million a year earlier. The company held $624.7 million in cash, cash equivalents and investments at the end of September.
Why it matters
Spending on administrative and commercial functions rose sharply as the company prepares for a possible launch of lorundrostat for hypertension. The company's cash position is expected to fund operations, including a potential launch, into 2028.
General and administrative expenses rose to $37.4 million from $9.7 million, while research and development fell to $22.7 million from $31.5 million. Cash, equivalents and investments totaled $624.7 million, down from $656.6 million at the end of 2025.
The players
Mineralys Therapeutics Inc.
A clinical-stage pharmaceutical company headquartered in Radnor, Pennsylvania, developing lorundrostat as a treatment for hypertension.
The details
The increase in administrative costs reflected $15.4 million in higher professional fees and $11.4 million in added personnel expenses. Research spending fell because the pivotal lorundrostat clinical program was completed in the second quarter of 2025. The company also entered a senior secured term loan in June 2026, which added about $3.2 million in interest expense.
Timeline
Q2 2025: Pivotal lorundrostat clinical program completed.
June 2026: Senior secured term loan entered.
Sept. 30, 2026: Quarter ended with $57.3 million net loss reported.
Nov. 6-9, 2026: Transform-HTN findings to be presented at AHA Scientific Sessions in Chicago.
Dec. 22, 2026: FDA decision date for lorundrostat.
Healthcare Landscape
Mineralys is spending ahead of a Prescription Drug User Fee Act decision on lorundrostat, a hypertension drug whose pivotal Launch-HTN trial found 46% of participants on the 50-milligram dose reached systolic blood pressure below 130 mm Hg. The company's commercial buildout is a bet that payers and physicians will adopt a new aldosterone synthase inhibitor for uncontrolled hypertension.
If approved, lorundrostat would add a new oral option for adults with uncontrolled hypertension, a group that often needs multiple medications. Patients and prescribers would need to see how coverage and cost are handled once a commercial launch begins.
The takeaway
Investors and patients should watch the December FDA decision closely, since it will determine whether Mineralys's spending turns into a marketed product. The company's cash runway into 2028 gives it time, but the outcome of that review will set the direction of its finances.
What happens next
The FDA is scheduled to decide on lorundrostat on Dec. 22, 2026, and Transform-HTN findings will be presented at the AHA Scientific Sessions in Chicago from Nov. 6 to 9, 2026.
Further reading
For more on the state's pharmaceutical sector, see Healthcare coverage in Pennsylvania.










